tailieunhanh - Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: Predictors and pitfalls

For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a useful treatment for MTC, is usually well tolerated, but evidence on its effectivity is very limited. | Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma Predictors and pitfalls

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN